A case series discusses how a liver biopsy may prove instrumental in determining if ruxolitinib therapy should be discontinued or continued in patients with myelofibrosis (MF) and polycythemia vera (PV) experiencing liver damage.
A liver biopsy may prove instrumental in determining if ruxolitinib therapy should be discontinued or continued in patients with myelofibrosis (MF) and polycythemia vera (PV) experiencing liver damage, according to a recently published case series.
With the growing use of ruxolitinib in the treatment of MF and PV, clinicians may be puzzled as to whether ruxolitinib is the cause of hepatic enzyme elevations or is, in fact, helpful for the treatment of hepatic dysfunction arising from extramedullary hematopoiesis (EMH). EMH is important to identify, since it is a disease manifestation that may respond favorably to ruxolitinib therapy.
The recently published report examined 4 cases of patients without known liver disease or pathology receiving ruxolitinib who experienced hepatocellular damage and had a liver biopsy performed that clarified their subsequent management. Relevant histologic images of liver biopsies were reviewed by a liver pathologist and reported to a multidisciplinary team including hepatology and hematology. A variety of liver damage was found, including EMH, obliterative portal venopathy, and drug-induced liver injury (DILI), all of which had treatment implications.
Providers should be aware of the potential causes of liver damage in this population and initiate prompt referral and liver biopsy. Although some liver abnormalities can be attributed to ruxolitinib itself, most of the patients had damage as a consequence of EMH. The report said a liver biopsy may be instrumental in determining if ruxolitinib therapy should be discontinued or continued, particularly in the case of DILI.
There was also a possible case of ruxolitinib-associated DILI, but there are no known mechanisms to explain possible hepatotoxicity with this agent. If DILI is suspected with ruxolitinib exposure, discontinuation may be warranted. However, abrupt discontinuation of ruxolitinib can lead to a serious and potentially life-threatening withdrawal syndrome characterized by worsening cytopenias and progressive splenomegaly, the most severe form of which can mimic septic shock with hemodynamic instability.
If ruxolitinib is discontinued, it should be done as a taper under close supervision and in certain cases overlapped with prednisone to blunt the potential cytokine rebound phenomenon. Therefore, a liver biopsy to diagnose DILI is of key importance before considering withdrawal of ruxolitinib.
Ruxolitinib is a Janus-kinase inhibitor and is the sole FDA-approved therapy for patients with intermediate-/high-risk MF; it is also approved to treat patients with PV that have previously failed therapy with hydroxyurea. MF itself is also associated with hepatic dysfunction.
Reference
Tremblay D, Putra J, Voggel A, Winters A, Hoffman R, Schiano TP. The implications of liver biopsy results in patients with myeloproliferative neoplasms being treated with ruxolitinib [published online January 6, 2019]. Case Rep Hematol. doi.org/10.1155/2019/3294046.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More